Contributing to the advancement of healthcare
Ever since its founding in 1968, Sysmex has created a wide spectrum of products and services in the diagnostics field based on advanced technologies. Diagnostics play a vital role in healthcare by enabling the early detection of disease, the determination of treatment and the prevention of illness. At present, Sysmex’s products are being used at healthcare facilities in over 170 countries around the world.
The healthcare environment is currently undergoing dramatic changes due to changing social structures. In emerging countries, economic development and population growth are rapidly increasing healthcare needs. On the other hand, advanced countries are facing declining birthrates and aging populations, and individual values on health are increasingly diversifying. Sysmex is responding to such changes and striving to create innovative values with the aim of contributing to the advancement of healthcare. We want to respond to the wishes of people across the globe: “to stay healthy”.
In fiscal 2010, Sysmex obtained approval from the Ministry of Health, Labour and Welfare of Japan to manufacture and market reagents for the detection of colon cancer lymph node metastasis. By providing more accurate results in a shorter time, this system helps healthcare professionals to make objective and appropriate decisions on post-operative treatment.
Building the trust and confidence of all stakeholders
Sysmex believes that continually building trust and confidence is the basis of fulfilling our corporate social responsibility (CSR). Based on our Group Corporate Philosophy, the “Sysmex Way”, and our Core Behaviors, we conduct various activities in an effort to bring solid trust and confidence to our customers, business partners, employees, shareholders, and other stakeholders. In addition to contributing to the health of people around the world, we actively carry out environmental activities and social contribution activities.
In fiscal 2010, we continuously conducted VQ (Value Quest) Activities, through which all of our employees worldwide think about and propose ways to further strengthen our abovementioned efforts. For example, we have participated in the Kobe Medical Industry Development Project and continued to provide support to social contribution activities carried out on a global scale by NPOs and NGOs who work actively in the fields of healthcare, education and the environment. In fiscal 2010, we decided to become the special sponsor of the “Kobe Marathon 2011”, which will take place in Kobe in November 2011, concurring with the purpose of the event: “To express gratitude to everyone who supported the recovery after the Great Hanshin-Awaji Earthquake”.
Participating in the United Nations
Global Compact
In order to further promote CSR activities as a global corporation, Sysmex participated in the United Nations Global Compact in February 2011.
We took this opportunity to reconfirm our social responsibility and to incorporate and implement the UN Global Compact’s ten principles in the areas of human rights, labor, the environment and anti-corruption into our activities as a means of further building the trust and confidence of people across the globe.
Promoting Eco-Vision and
our mid-term environmental activities
In response to global environmental issues, Sysmex formulated the Group Environmental Action Plan (Sysmex Eco-Vision 2020) in April 2010. This Action Plan set forth long-term environmental objectives for fiscal 2020.
It also sets targets focusing on reducing the environmental burden in each stage of the product lifecycle, which consists of product design, production, sales, product use and disposal. Through these efforts, we are striving to save energy and resources in our business activities and to actively develop and distribute eco - friendly products and services.
Creating innovative values based on our
mid-term management plan
This year, Sysmex formulated a new mid-term management plan. Guided by the new plan, we will strive to further improve the usability of our products, provide high clinical value, and strengthen our response to healthcare needs around the world.
In emerging countries, where the establishment of the healthcare infrastructure is urgently needed, we will provide products and services that meet local healthcare needs, and focus on improving our support systems. In the area of molecular diagnosis pertaining to cancer and other diseases, we aim to create original testing technologies in an effort to contribute to the further advancement of healthcare.
Supporting disaster-stricken areas
We would like to express our heartfelt condolences to all the victims of the Great Tohoku Pacific Earthquake, and our sincere sympathy to those who have been affected by this terrible tragedy including those who were compelled to leave their homes and businesses.
Healthcare infrastructure is an essential and critical factor in disaster recovery. We have provided as much support as possible for the early restoration of devastated healthcare facilities and the healthcare support network through the free use of testing instruments and the provision of reagents.
It is our hope that those affected by the tragedy will be able to return to their normal lives in a relatively short time. We would also like to take this opportunity to express our deepest gratitude for the warm support for disaster victims that arrived from overseas.
We will continue in our efforts to achieve sustainable development of the Group and the global community.
We ask our stakeholders for their continued support and generous understanding of all of our endeavors.
| |
 |
|
Hisashi letsugu |
|
President and CEO |
